Skip to Main Content

Pfizer’s experimental gene therapy to treat Duchenne muscular dystrophy appeared to improve muscle function in a study of nine boys, but also resulted in serious drug reactions in three of those children, the company said Friday.

The data are being presented at a virtual session of the American Society of Gene & Cell Therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!